Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
The progressive neurological condition affects more than six million people worldwide
Read Moreby Jen Brogan | May 1, 2024 | News | 0
The progressive neurological condition affects more than six million people worldwide
Read Moreby Jen Brogan | Apr 2, 2024 | News | 0
Two out of three people with the neurodegenerative condition experienced delirium in hospital
Read Moreby Jen Brogan | Mar 21, 2024 | News | 0
The globally fast-growing progressive neurological condition affects around 153,000 people in the UK
Read Moreby Jen Brogan | Mar 14, 2024 | News | 0
Affecting 55 million people globally, dementia impairs the ability to remember, think or make decisions
Read Moreby Jen Brogan | Mar 13, 2024 | News | 0
The progressive neurological disorder affects approximately 12,400 people in Scotland
Read Moreby Jen Brogan | Feb 19, 2024 | News | 0
The study aims to improve the representation of ethnic diversity within Parkinson’s research
Read Moreby Jen Brogan | Feb 2, 2024 | News | 0
Dopamine neuron senescence is a hallmark of Parkinson’s disease
Read Moreby Jen Brogan | Dec 20, 2023 | News | 0
The findings could lead to new treatments to target the mTOR and ease PD symptoms
Read Moreby Jen Brogan | Oct 27, 2023 | News | 0
Around 145,000 people in the UK are living with Parkinson’s disease
Read Moreby Jen Brogan | Oct 17, 2023 | News | 0
The two projects will investigate the potential causes of Parkinson’s disease
Read Moreby Jen Brogan | Sep 21, 2023 | News | 0
The report outlines ways the government can help patients with Parkinson’s disease
Read Moreby Jen Brogan | Sep 15, 2023 | News | 0
The method could also be beneficial for Parkinson’s disease and strokes
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479